TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares. (more…)
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held earlier today, all resolutions put to shareholders were duly passed.
(more…)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 18 November 2016 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”)
(more…)
Notice is hereby given that the Annual General Meeting of Bioventix Plc (the “Company”) will be held at The Winchester Suite, Farnham Castle, Farnham, Surrey, GU9 0AG on Wednesday 7 December 2016 commencing at 2.00pm for the purpose of considering and, if thought fit, passing the following resolutions of which resolutions 1 to 4 (inclusive) will be proposed as ordinary resolutions and resolutions 5 and 6 will be proposed as special resolutions.
(more…)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2016. (more…)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, announces a trading update.
(more…)
TR-1: Notification of major interest in shares. (more…)
Bioventix plc (AIM: BVXP) announces that it has today applied for 47,725 ordinary shares of 5 pence each (the “Option Shares”) to be admitted to trading on AIM (“Admission”). It is expected that Admission will occur and that dealings will commence in the Option Shares on 18 July 2016. (more…)
TR-1: Notification of major interest in shares. (more…)